Your browser is no longer supported. Please, upgrade your browser.
CEMI Chembio Diagnostics, Inc. weekly Stock Chart
CEMI [NASD]
Chembio Diagnostics, Inc.
Index- P/E- EPS (ttm)-0.93 Insider Own0.20% Shs Outstand17.20M Perf Week20.81%
Market Cap89.24M Forward P/E- EPS next Y-0.64 Insider Trans0.00% Shs Float13.94M Perf Month-53.66%
Income-15.90M PEG- EPS next Q-0.22 Inst Own41.20% Short Float14.84% Perf Quarter-38.62%
Sales33.00M P/S2.70 EPS this Y-48.00% Inst Trans-3.34% Short Ratio0.90 Perf Half Y-8.33%
Book/sh1.05 P/B3.98 EPS next Y23.50% ROA-30.80% Target Price- Perf Year-29.63%
Cash/sh0.52 P/C7.97 EPS next 5Y25.00% ROE-66.10% 52W Range2.25 - 15.89 Perf YTD-8.33%
Dividend- P/FCF- EPS past 5Y-46.60% ROI-30.50% 52W High-73.69% Beta2.30
Dividend %- Quick Ratio2.10 Sales past 5Y4.50% Gross Margin33.40% 52W Low85.78% ATR0.82
Employees295 Current Ratio3.50 Sales Q/Q-18.80% Oper. Margin-44.10% RSI (14)34.05 Volatility11.39% 10.65%
OptionableYes Debt/Eq1.01 EPS Q/Q-77.20% Profit Margin-48.00% Rel Volume9.67 Prev Close3.28
ShortableYes LT Debt/Eq0.99 EarningsMay 04 AMC Payout- Avg Volume2.31M Price4.18
Recom3.00 SMA20-29.82% SMA50-55.44% SMA200-32.20% Volume22,298,852 Change27.44%
Jun-17-20Downgrade The Benchmark Company Speculative Buy → Hold
Jun-17-20Downgrade Craig Hallum Buy → Hold
Jun-17-20Downgrade Canaccord Genuity Buy → Hold $7
May-26-20Initiated Robert W. Baird Outperform $21
Mar-04-20Reiterated The Benchmark Company Speculative Buy $9 → $6
Mar-04-20Reiterated The Benchmark Company Speculative Buy $9 → $5
Dec-19-18Initiated Dougherty & Company Buy
Aug-11-16Reiterated The Benchmark Company Speculative Buy $10 → $9
Apr-18-16Reiterated The Benchmark Company Speculative Buy $6 → $8
Nov-04-15Initiated The Benchmark Company Speculative Buy $6
Sep-10-13Resumed The Benchmark Company Speculative Buy $7
Jul-03-20 09:00AM  
Jul-02-20 04:15PM  
03:40PM  
01:00PM  
12:13PM  
Jul-01-20 07:45PM  
06:30PM  
06:25PM  
06:00PM  
05:57PM  
05:00PM  
03:15PM  
01:55PM  
01:40PM  
01:32PM  
01:00PM  
06:51AM  
Jun-30-20 07:55PM  
07:52PM  
06:22PM  
01:20PM  
12:01PM  
06:39AM  
Jun-29-20 08:20PM  
04:50PM  
12:25PM  
12:09PM  
11:00AM  
02:01AM  
12:20AM  
Jun-28-20 10:00AM  
Jun-27-20 04:12PM  
10:17AM  
Jun-26-20 07:30PM  
06:46PM  
03:43PM  
02:46PM  
02:15PM  
01:35PM  
01:20PM  
06:30AM  
Jun-25-20 11:25PM  
07:48PM  
07:28PM  
06:30PM  
04:35PM  
03:55PM  
01:35PM  
01:00PM  
07:50AM  
07:00AM  
Jun-24-20 11:24PM  
07:59PM  
07:45PM  
07:00PM  
06:10PM  
05:35PM  
04:30PM  
03:57PM  
02:44PM  
01:20PM  
01:20PM  
01:00PM  
12:00PM  
11:00AM  
Jun-23-20 05:35PM  
04:25PM  
03:15PM  
02:57PM  
12:55PM  
11:44AM  
11:40AM  
11:18AM  
11:00AM  
09:45AM  
09:00AM  
Jun-22-20 08:35PM  
08:10PM  
06:26PM  
02:45PM  
02:30PM  
02:20PM  
01:56PM  
01:03PM  
11:00AM  
09:19AM  
08:45AM  
Jun-20-20 07:00PM  
Jun-19-20 07:05PM  
04:26PM  
01:33PM  
11:55AM  
11:30AM  
11:00AM  
10:00AM  
03:05AM  
Jun-18-20 08:15PM  
06:27PM  
05:50PM  
05:21PM  
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and Shire Human Genetic Therapies, Inc. to develop a novel POC diagnostic test. It also has a strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus, and IgM and IgG antibodies on the LumiraDx and Chembio DPP platforms. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Potthoff John GaryDirectorNov 11Buy4.4410,00044,40037,772Nov 13 07:21 PM